Pharma BD Deal Intelligence
Absci and AstraZeneca sign deal on AI-powered cancer antibody drug worth up to $247 million using generative AI for drug design
AstraZeneca bets $247M that AI can create cancer antibody partnering with Absci zero-shot generative AI drug design technology platform
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration ... first announced in December…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca entered a collaboration with Absci Corporation (Nasdaq: ABSI), announced December 2023, to advance an AI-designed oncology antibody using Absci's Integrated Drug Creation platform and its de novo 'zero-shot' generative AI models, which design antibodies to bind a specified target without relying on existing antibody data. The agreement is valued at up to $247 million across an upfront commitment, R&D funding and milestone payments, plus royalties on any resulting product sales. On November 12, 2024, Absci delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling the first milestone under the collaboration; the partnership remains active and is listed among Absci's current pharma collaborations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Absci Corporation (this deal) | 2023 | $247M | 54 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Oncology deals